Phase II Trial of Antiepidermal Growth Factor Receptor Antibody C225 in Patients with Advanced Renal Cell Carcinoma
- 1 February 2003
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 21 (1), 99-101
- https://doi.org/10.1023/a:1022928612511
Abstract
Fifty-five patients with metastatic renal cell carcinoma (RCC) were treated on a multicenter, single-arm Phase II trial. Patients received single-agent Cetuximab (C225) administered by intravenous infusion at a loading dose of 400 or 500 mg/m2 followed by weekly maintenance doses at 250 mg/m2. None of the patients treated with C225 achieved either a complete or partial response. The median time to progression was 57 days. The most frequently reported grade 3 or 4 toxicity treatment-related adverse events were acne (17%) and rash or dry skin (4%). The lack of clinical response or suggestion of prolonging time to progression compared to historical data with interferon-alfa supports no further study of single-agent C225 in patients with metastatic RCC.Keywords
This publication has 6 references indexed in Scilit:
- Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2002
- Systemic therapy for renal cell carcinoma.2000
- SYSTEMIC THERAPY FOR RENAL CELL CARCINOMAJournal of Urology, 2000
- Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice.1998
- Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.1997
- The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma.1994